专利检索_...来源于阿黑皮素原脑啡肽原或强啡肽原专利检索_...来源于阿黑皮素原脑啡肽原或强啡肽原专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
161	METHOD FOR STIMULATING PROFILERATION OF COLON CELLS USING POMC 76-103	EP95912594	1995-02-23	EP0785990A4	1997-09-17	NICE EDWARD C; JAMES R; SIMPSON R; BURGESS ANTONY W; WHITEHEAD ROBERT H

162	USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY	US17831887	2022-06-03	US20220339239A1	2022-10-27	Heather A. Halem; Michael Dewitt Culler; Andrew Butler
The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
163	CANCER THERAPY	US17366830	2021-07-02	US20220168324A1	2022-06-02	Rebecca Lambert Bent
The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities.
164	CANCER THERAPY	US16179722	2018-11-02	US20190175626A1	2019-06-13	Rebecca Lambert Bent
The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities.
165	MELANOCORTINS AND METHODS OF USE THEREOF	US16077710	2016-12-14	US20190054150A1	2019-02-21	Ronald BERENSON; Christopher H. CLEGG
In some aspects, the present disclosure provides compositions and methods for treating disease, e.g., inflammatory disease. Compositions herein comprise one or more polypeptide fragments of proopiomelanocortin or variants thereof. The one of more polypeptide fragments of proopiomelanocortin or variants thereof may be linked by a linker, e.g., a peptide linker, to form a fusion polypeptide.
166	Use of Melanocortins to Treat Insulin Sensitivity	US15801432	2017-11-02	US20180303899A1	2018-10-25	Heather A. HALEM; Michael DeWitt CULLER; Andrew A. BUTLER
The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
167	Use of melanocortins to treat insulin sensitivity	US15242866	2016-08-22	US09827286B2	2017-11-28	Heather A. Halem; Michael DeWitt Culler; Andrew A. Butler
The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
168	Methods related to the treatment of neurodegenerative and inflammatory conditions	US14323557	2014-07-03	US09498511B2	2016-11-22	Jau-Shyong Hong; Liya Qin; Guorong Li; Michelle Block; Wei Zhang; Po-See Chen; Giia-Shuen Peng
The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.
169	Sustained-release composition containing peptides as active ingredient	US14126365	2012-06-13	US09415012B2	2016-08-16	Joël Richard; Faïza Laredj; Marie-Madeleine Baronnet; Didier Nourrisson; Jeremiah Harnett; Béatrice Hacher; Nathalie Mondoly; Laurent Bertocchi
The present invention relates to a sustained-release drug composition consisting essentially of microparticles of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium.
170	Methods and compositions for treating conditions related to lack of blood supply, shock, and neuronal injuries	US14086492	2013-11-21	US09387162B2	2016-07-12	Cuthbert O. Simpkins
A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure.
171	Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor	US13660129	2012-10-25	US09375458B2	2016-06-28	Ian S. Zagon; Patricia J. McLaughlin; Jill P. Smith
The present invention relates to pharmaceutical compositions for treating neoplasias in an animal or human comprised of a carrier and therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin, referred to as opioid growth factor. Also provided are methods of treating neoplasias in an animal or human in need of such treatment, comprising the administration to the animal or human therapeutically effective amounts of a pharmaceutical composition comprised of a carrier and therapeutically effective amounts of at least one neoplasia-treating agent, such as a chemotherapeutic agent or radiation, along with opioid growth factor.
172	Use of melanocortins to treat insulin sensitivity	US12740917	2008-11-05	US09155777B2	2015-10-13	Heather A. Halem; Michael Dewitt Culler; Andrew A. Butler
The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
173	MEDICAMENT	US13544413	2012-07-09	US20130203669A1	2013-08-08	Deirdre McIntosh
Analysis of a goat serum product with many therapeutic effects is described. The product is identified as containing proopiomelanocortin (POMC) and Corticotropin releasing factor (CRF) peptides, as well as breakdown products of these peptides. We describe methods of treatment of diseases including cancers, multiple sclerosis, and neural disorders using these peptides and their products, as well as medicaments including such peptides and methods of producing the peptides.
174	Acetylated therapeutic procytotoxins	US11131443	2005-05-18	US07550426B2	2009-06-23	Thomas E. Wagner; Xianzhong Yu
A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group, and an acetyl group. These agents are useful in treating cancer, especially prostate cancer.
175	Polymer-based sustained release device	US11104877	2005-04-13	US20050271702A1	2005-12-08	Steven Wright; Troy Christensen; Thean Yeoh; Michael Rickey; Joyce Hotz; Rajesh Kumar; Henry Costantino
This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
176	Control of cancer growth through the interaction of [Met.sup.5 ]-enkephalin and the zeta (.zeta.) receptor	US827481	1997-03-27	US06136780A	2000-10-24	Ian S. Zagon; Patricia J. McLaughlin
The present invention is related to the treatment and prevention of cancer including particularly gastrointestinal cancer. More specifically, the present invention describes the use of naltrexone, naloxone and the pentapeptide growth factor [Met.sup.5 ]-enkephalin to inhibit and arrest the growth of cancer. Such efficiency has been discovered to be a consequence of the functional manipulation of the zeta (.zeta.) opioid receptor through endogenous [Met.sup.5 ]-enkephalin. This receptor has been determined to be present in growing cancers such as pancreatic and colon cancer, for example.
177	Ischemic preconditioning	US080665	1998-05-18	US6103722A	2000-08-15	Jo El Schultz; Garrett Gross
Methods and pharmaceutical compositions of matter are disclosed and claimed relating to cardioprotective effect mediated by delta (.delta.) opioid receptor agonists or more specifically delta-1 (.delta..sub.1)-opioid receptor agonists. Further, methods drawn to reducing ischemic damage to organs and tissues having delta (.delta.) opioid receptor agonists or more specifically delta-1 (.delta..sub.1)-opioid receptors are disclosed and claimed. Specifically, methods and pharmaceutical compositions of matter are taught as a means of providing cardioprotective treatment through the administration of delta (.delta.) opioid receptor agonists or more specifically delta-1 (.delta..sub.1)-opioid receptor agonists, such as TAN67(-). Said methods and pharmaceutical compositions are envisioned as a means of reducing myocardial infarction arising from the onset and sequelae of myocardial ischemia.
178	Methodology for eliciting an analgesic response in a living subject	US631434	1996-04-12	US5891842A	1999-04-06	Richard M. Kream
The present invention provides a method for eliciting an opioidal analgesia in a living subject using two classes of chemical compositions previously thought to have directly contradictory and physiologically antagonistic roles in the spinal analgesic process. The present methodology relies upon a concurrent administration of an opioid in marginal concentrations in combination with marginal doses of substance P or its related entities which function in a synergistic relationship and mechanism of action. The methodology relies upon a powerful potentiation and enhancement of an opioid-mediated response by the enhancing action of substance P to modulate or eliminate pain and other nociceptive responses, as well as inducing anesthesia.
179	Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphanin FQ)	US927328	1997-09-11	US5840696A	1998-11-24	Howard Lippton
Nociceptin in a method of controlling water retention in a patient. More particularly, the use and administration of nociceptin as a free-water diuretic that produces a free-water diuresis for the control of water retention in patients.
180	Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies	US737902	1996-11-21	US5811451A	1998-09-22	Paolo Minoia; Raffaele Luigi Sciorsci
The combined use of opiate antagonists and of calcium salts for the preparation of medicaments for the treatment of endorphin-mediated pathologies is described.

4 5 6 7 8 9 10 11 12 13

IPRDB

热门服务

关于我们

友情链接

联系方式